


AMENDMENT TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of general formula I:



where:

R₁ is selected from the group formed by H, -(CH₂)₃-, -(CH₂)₄-, -CH₂-S-CH₂-, -S-CH₂-CH₂-;

R₂ is selected from the group formed by N, S;

n has a value of 0 or 1;


Z is selected from the group formed by C2-C10-alkyl, C2-C10-alkenyl, C2-C10-alkinyl;

R₃ is selected from the group formed by H, C1-C10-alkyl, aryl, aralkyl;

m has a value of 0 to 2;

R₄ is selected from the group formed by O, CH₂;

R₅ is selected from the group formed by:



where:

R_6 is selected from the group formed by H, C1-C5-alkyl, C1-C5-alkoxyl, OH, F, Cl, Br, I;


X is selected from the group formed by O, S, NH, NCH_3 ;

Y is selected from the group formed by O, NH;

W is selected from the group formed by S, NH;

and their salts and solvates.


2. (Original) A compound according to claim 1, characterized in that Z represents a C2-C10-alkyl group and R_5 is selected from the group formed by:



where:

R_6 is selected from the group formed by H, C1-C5-alkyl, C1-C5-alkoxyl, OH, F, Cl, Br, I.

3. (Currently Amended) A compound according to claim 1 ~~any of claims 1 to 2~~, characterized in that Z is butyl, R_3 is H and R_5 is selected from the group formed by:




where:

R_6 is selected from the group formed by H, C1-C5-alkyl, C1-C5-alkoxyl, OH, F, Cl, Br, I.


4. (Currently Amended) A process to prepare a compound according to claim 1 ~~any one of claims 1 to 3~~, characterized in that:

(A) the intermediate halogen derivatives II are made to react, where L means Cl, Br, with amines III in acetonitrile, according to the scheme of reaction I:



Scheme I

(B) the intermediate amines IV are made to react with suitable halogen derivatives V, where L means Cl, Br, in acetonitrile, according to the scheme of reaction II:



Scheme II

where the definitions of R_1 , R_2 , n , Z , m , R_4 and R_5 in these schemes are identical to those previously made for the products of the invention.

5. (Currently Amended) [[P]] A process according to claim 4, characterized in that those compounds with R_3 different from H are obtained by alkylation of the analogues wherein R_3 is hydrogen.

6. (Currently Amended) [[P]] A pharmaceutical composition characterized in that it comprises a therapeutically effective quantity of any of the compounds defined in claim 1, the preceding claims 1 to 3 together with a pharmaceutically acceptable carrier or excipient.

7. (Currently Amended) [[U]] The use of a compound according to claim 1 any of the preceding claims 1 to 3, for the production of a medicine for the treatment and/or prevention of pathological states wherein the 5-HT_{1A} receptor agonists are indicated.

8. (Currently Amended) [[U]] The use of a compound according to claim 1 any of the preceding claims 1 to 3, for the production of a medicine for the treatment and/or prophylaxis of cerebral damage produced by thromboembolic stroke or cranium-brain traumatic injuries.